Alerta

A COMPOUND FOR PREPARING LIPID NANOPARTICLES ENCAPSULATING AN AGENT, NANOPARTICLE COMPOSITION COMPRISING SAID COMPOUND AND RELATED METHODS THEREOF

Resumen de: WO2025080209A1

There is provided a compound represented by general formula (1) for preparing lipid nanoparticles encapsulating a therapeutic, prophylactic and/or biological agent: wherein AR comprises a unit from a poly(amino acid); R1 and R2 are each independently a hydrophobic group; R3, R4, and R5 are each independently H, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; R7 is –H or –C(=O)R8, wherein R8 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted alkoxy; m ≥ 1; and n ≥ 1.

GLUTAMIC ACID-BASED LIPIDS, LIPID NANOPARTICLE CONTAINING GLUTAMIC ACID-BASED LIPIDS, AND FORMULATIONS THEREOF

Resumen de: WO2025076625A1

Provided is a glutamic or glutaric acid-based ionizable lipid compound of Formula (I) or a pharmaceutically acceptable salt thereof. The compound can be used to obtain lipid nanoparticles. In some embodiments, the lipid nanoparticle can comprise (a) from about 40 to about 100 mol % of the compound of Formula (I); (b) from 0 to about 20 mol % of a neutral lipid; (c) from 0 to about 50 mol % of a helper lipid; (d) from 0 to about 5 mol % of a polymer-conjugated lipid; and (e) from 0 to about 10 mol % of a hydrophobic component; wherein the mol % are based on the total lipids present in the nanoparticle. In some embodiments, the ionizable lipid compound is a glutamic acid-based ionizable lipid compound.

IONIZABLE LIPIDS AND LIPID NANOPARTICLES FOR RNA DELIVERY

Resumen de: WO2025077836A1

Provided herein is novel ionizable cationic lipid compound that can be assembled with other helper lipids, such as phospholipids, structural lipids, and polymer conjugated lipids capable of reducing aggregation, to form lipid nanoparticles for delivery of therapeutic RNA both in vitro and in vivo. These compounds contain a thiourea group in the linker between the lipid group and the head group (-NRc-C(S)-NRd-).

ENGINEERING ANTIGEN-SPECIFIC T CELLS FOR CAR T CELL THERAPY BY ANTIGEN-PRESENTING LIPID NANOPARTICLES

Resumen de: WO2025081194A2

Antigen-presenting nanoparticles and methods of engineering CAR T cells and treating and/or preventing cancer using the same.

LIPID NANOPARTICLES

Resumen de: WO2025080945A1

The present disclosure relates to lipid nanoparticles and methods of delivering active agents to target organs, tissues, or cells by utilizing the lipid nanoparticles.

MEANS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE EFFECTOR CELLS

Resumen de: WO2025078699A1

The current disclosure relates to targeted delivery of agents to T cells and/or NK cells. Highly suitable targeting domains were meticulously identified that allow for an agent, such as DNA and/or RNA, to be delivered to T cells and/or NK cells. As shown, when lipid nanoparticles were provided with such a targeting domain, nucleic acid comprised in said lipid nanoparticles was highly efficiently and specifically delivered. This allows for engineering of T cells and/or NK cells, highly useful in medical treatments for cancer.

CARBONATE CONTAINING LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS

Resumen de: EP4793267A1

The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

CARRIER CAPABLE OF TARGETING CELL AT SUBSET LEVEL AND METHOD FOR PRODUCING SAME

Resumen de: EP4792807A1

0001 A problem to be solved by the present invention is to provide a carrier capable of being selectively delivered to cells at a subset level, which has not yet been realized by conventional art, and to provide a method for producing the carrier. The present invention relates to a carrier for selective delivery to a target cell having multiple types of target receptors on its surface, the carrier having multiple types of ligands, wherein each type of ligand binds to one of the multiple types of target receptors, wherein the carrier is taken up by the target cell that has all the multiple types of target receptors, but is not taken up by a cell that lacks at least one of the multiple types of target receptors; a method for producing the carrier; and the like.

LOW-SUGAR CORONAVIRUS VACCINE AND METHODS THEREOF

Resumen de: WO2025080565A1

The present disclosure relates to a low glycosylated spike protein and a vaccine designed to express the spike protein in vivo. The present disclosure also teaches a method for generating an immune response by utilizing the low glycosylated spike protein, which provides a broader protection across different variants. A method for identifying a glycan-shielded conserved peptide of a glycoprotein is also disclosed.

IMMUNE CELL TARGETED DELIVERY VEHICLES AND METHODS OF USE THEREOF

Resumen de: WO2025080672A1

The present invention relates to methods and compositions comprising a delivery vehicle conjugated to a chemokine or cytokine ligand, wherein the delivery vehicle comprises at least one agent, and wherein the targeting domain specifically binds to the surface of a target immune cell. The invention also relates to methods for treating or preventing diseases and disorders, including cancers, infectious diseases, and immunological disorders, using the described delivery vehicle for delivery of a therapeutic agent.

IONIZABLE LIPIDS FOR IMPROVED MRNA DELIVERY

Resumen de: WO2025080867A1

Provided herein are ionizable cationic lipids and lipid nanoparticle compositions comprising a lipid component comprising the same. Also, provided herein is a method of treating or preventing a disease or disorder in a subject in need thereof, the method comprising administering an effective amount of the lipid nanoparticle composition disclosed herein.

LIVER ASIALOGLYCOPROTEIN RECEPTOR TARGETED LIPID AND USES THEREOF

Resumen de: WO2025080572A1

A compound having the structure (I), (II), (III), or (IV) is provided: (I), (II), (III), (IV) ) where in these structures, (I), (II), (III), and (IV), each R1 is independently selected from aliphatic alkyl C4-C100 groups optionally substituted with one or more of alkenyl, alkynyl, hydroxyl, amide, ester, and/or ether groups; R2 is selected from -OCH2CH2-p or (A); R3 is selected from Formula (V) and Formula (VI): (V, (VI). M+ is selected from an alkali metal ion, an alkaline earth metal ion, or a primary, secondary or tertiary ammonium ion; and m, p, and s are independently selected from integers from 1 to 120. The compound is useful as a liver asialoglycoprotein receptor-targeted therapeutic agent in the form of a lipid nanoparticle, a liposome or a micelle including a drug or oligonucleotide.

高純度酸化鉄ナノ粒子の細胞での生産

Resumen de: EP3633042A1

A method for removing at least one impurity from metal-based nanoparticles, including at least two heating steps. During step 1, the temperature of the nanoparticles is increased to a temperature T₁, and is then maintained at T₁during a heating time that is included between 1 second and 20 years, where T₁is included between 50 °C and 300 °C.During step 2, the temperature of the nanoparticles is increased to a temperature T₂, and is then maintained at T₂during a heating time that is included between 1 second and 20 years, where T₂is included between 300 °C and 600 °C.

脂質ナノ粒子の凍結乾燥製剤及び液体製剤

Resumen de: WO2025026304A1

Provided are lyophilized formulations of lipid nanoparticles comprising a cationic lipid and a cryoprotectant combination, which contains sucrose and a non-polar amino acid.

単純ヘルペスウイルス糖タンパク質Ｅ及び／又は糖タンパク質Ｉ抗原をコードするＲＮＡ組成物並びにその使用

Resumen de: WO2025030134A1

Disclosed herein are compositions comprising (a) a nucleoside-modified polyribonucleotide encoding a Herpes Simplex Virus-2 (HSV-2) glycoprotein E (gE) antigen or immunogenic fragment thereof, (b) a nucleoside-modified polyribonucleotide encoding an HSV-2 glycoprotein I (gI) antigen or immunogenic fragment thereof, or (c) a combination thereof. Further disclosed are methods for using said compositions for treating an HSV infection.

操作されたキメラ融合タンパク質組成物及びその使用方法

Resumen de: WO2025007059A1

Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.

一种纳米姜黄素复合物及其制备方法和应用

Resumen de: CN122582125A

本发明提供了一种纳米姜黄素复合物及其制备方法和应用，属于生物医药技术领域。本发明提供的纳米姜黄素复合物中，插入功能性小分子肽段的神经元细胞膜作为外壳，内部包裹负载姜黄素的纳米粒子，能够显著提高姜黄素的溶解度和稳定性，促进其穿过血脑屏障并在脑组织中富集，同时有效抑制α‑突触核蛋白的磷酸化和异常聚集，从而在体内外模型中均表现出对长期低氧诱导的慢性神经损伤的显著保护作用。本发明为低氧相关神经系统疾病的预防和治疗提供了新的药物策略和理论依据。

用于软骨再生的肽及其用途

Resumen de: WO2024122717A1

The present application relates to a peptide having cartilage regeneration effects, and uses thereof, and provides: a peptide comprising an amino acid sequence represented by SEQ ID NO: 1 or Arg(R)-Leu(L)-Arg(R)-Ser(S); a composition for cartilage regeneration comprising the peptide; and a pharmaceutical composition for preventing or treating cartilage diseases, comprising the composition for cartilage regeneration as an active ingredient.

一种基于氟化壳聚糖的纳米载体PTX-FP@FCS-NPs的制备方法及应用

Resumen de: CN122582120A

本发明提供了一种基于氟化壳聚糖的纳米载体PTX‑FP@FCS‑NPs的制备方法，该方法为：合成氟化壳聚糖，将吐温80和氟化壳聚糖溶解于乙酸水溶液中，搅拌后，得到混合溶液，再将溶解后的5,10,15,20‑四(3,5‑双(三氟甲基)苯基)卟啉和紫杉醇加入混合溶液中，搅拌、离心，取沉淀物质，用蒸馏水洗涤沉淀物质后，得到基于氟化壳聚糖的纳米载体PTX‑FP@FCS‑NPs。本发明还提供了上述基于氟化壳聚糖的纳米载体PTX‑FP@FCS‑NPs的应用，用于制备改善肝细胞癌的药物，且与激光照射联合应用。本发明通过氟化修饰策略，构建了兼具清晰19F MRI/FLI双模态成像、pH/激光双响应药物释放特性以及高效共载紫杉醇和卟啉能力的纳米载体，该纳米载体在激光刺激下通过多机制协同作用，有效抑制肿瘤生长，且具有良好的生物安全性。

葡聚糖包覆的锰掺杂硫化钼纳米花/cGAMP纳米复合物及其制备方法与应用

Resumen de: CN122582121A

本申请涉及生物医药及医疗器械领域，公开了葡聚糖包覆的锰掺杂硫化钼纳米花/cGAMP纳米复合物及其制备方法与应用。所述纳米复合物为核‑壳结构，包括：Mn‑MoS2纳米花内核；cGAMP负载层，负载于所述Mn‑MoS2纳米花内核表面；以及葡聚糖涂层，包覆于所述cGAMP负载层表面。本申请采用具有压电/声响应特性的Mn–MoS2纳米花作为核心，并在外界超声刺激下产生压电极化与电荷分离，诱导或放大局部ROS生成。生物膜的EPS基质与细菌膜/壁对氧化应激高度敏感，ROS可对多糖链、蛋白与脂质产生氧化切断或结构破坏。

一种多活性物共包封仿生纳米囊泡及其制备方法

Resumen de: CN122582123A

本发明公开了一种多活性物共包封仿生纳米囊泡及其制备方法，属于生物医药技术领域。一种多活性物共包封仿生纳米囊泡，包括仿生纳米囊泡载体以及包封于所述仿生纳米囊泡载体内部的活性物体系；本发明采用氢化卵磷脂、植物鞘氨醇及植物固醇的三元脂质复配体系自组装形成仿生纳米囊泡载体，相较于传统“磷脂+胆固醇”二元脂质体，植物鞘氨醇的长链饱和结构嵌入磷脂分子间隙，与植物固醇协同发挥“双向流动性调节”作用，使脂质双层膜的致密性与机械强度显著增强。经30天常温储存试验验证，本发明囊泡的活性物渗漏率较传统脂质体降低72%以上，粒径变化率低于7%，有效解决了普通脂质体易聚集融合、内容物泄漏、货架期短的技术难题。

一种金属多酚网络结构桥接多糖缓释乳清蛋白质颗粒及其制备方法和应用

Resumen de: CN122582117A

本申请属于生物制药及药物制剂领域，具体涉及一种金属多酚网络结构桥接多糖缓释乳清蛋白质颗粒及其制备方法和应用。具体为首先将乳清蛋白质聚合为聚合乳清蛋白颗粒。然后使用原花青素与钙离子通过配位驱动的自组装形成金属多酚网络结构MPNs并涂覆在单个PWPI颗粒表面形成PWPI@MPNs。最后使用抗消化的多糖（透明质酸）包封在PWPI@MPNs表面形成盾牌，制出PWPI@MPNs/HA。实验发现，通过控制MPNs的用量，能够调控HA的吸附量，达到精细控制PWPI释放的效果，并在能够控制餐后血清氨基酸的水平。在肌少症动物模型中，PWPI@MPNs25/HA展现出对肌少症卓越的治疗效果。

一种适配多品类功能组合物的通用靶向递送系统、制备方法及应用

Resumen de: CN122582310A

本发明公开了一种适配多品类功能组合物的通用靶向递送系统、制备方法及应用，属于活性成分递送技术领域。本发明以靶向功能肽结合羟丙基‑β‑环糊精复合体系为核心，同时配套脂质体、外泌体、抗体偶联、刺激响应型递送系统；限定靶向功能肽分子量为120Da～5000Da，脂质体粒径为20nm～200nm。本发明可负载十二大类功能活性组分及中药经方、验方提取物，适配保健食品、营养补充剂、中药制剂与普通功能性食品。本发明经过试验优化载体参数与组合方式，并非现有技术简单叠加，全域适配性强、工艺简单、易于产业化，可有效提升活性成分稳定性与靶向递送效果，技术壁垒高，具备较高的应用与商业价值。

一种选择性免疫细胞亲和性的纳米递送系统及应用

Resumen de: CN122582093A

本发明提供了一种基于选择性免疫细胞亲和性的纳米递送系统及应用。该系统通过特定脂质成分与比例的处方设计，无需依赖靶向分子修饰，即可利用不同脂质组合的协同作用，精准调控纳米粒表面特性，从而实现对内源性外周血免疫细胞的选择性亲和与高效内源化摄取。该系统巧妙运用免疫细胞固有的炎症趋向性及器官归巢能力，实现纳米药物在体内的“搭便车”式主动递送，从而实现高效靶向骨髓、脾脏、肝脏、脑部、肺部和肿瘤等多种病灶器官的治疗。该系统构建简便、原料易得、工艺可放大，为多种急/慢性炎症性疾病靶向治疗提供了创新解决方案，具有显著的临床转化前景。

一种促进骨关节修复的间充质干细胞组合物及其制备方法

Nº publicación: CN122582265A 18/08/2026

Solicitante:

巴山泓（北京）医药科技有限公司北京帝康医药投资管理有限公司

Resumen de: CN122582265A

本发明涉及生物技术领域，具体是一种促进骨关节修复的间充质干细胞组合物及其制备方法，所述间充质干细胞组合物包括间充质干细胞、水凝胶骨架、肝素/透明质酸‑VEGF微球、改性PLGA纳米粒、纳米羟基磷灰石。在炎症损伤区，活化的中性粒细胞分泌MPO，MPO通过催化反应生成HOCl及ROS，作用于硫醚键，使微球从水凝胶骨架上脱离，氧化产生的亚砜基团使微球壳层亲水性增强，微球溶胀解聚，释放VEGF，启动血管生成，VEGF会招募大量炎症细胞，产生ROS，使改性PLGA纳米粒与水凝胶骨架间连接的硫缩酮键断裂，释放出TGF‑β3和sFlt‑1，sFlt‑1抑制剩余的VEGF活性，TGF‑β3能有效促进软骨形成，sFlt‑1与肝素形成稳定的复合物，实现sFlt‑1温和而持久的释放。